Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathogenesis of ascites in patients with cirrhosis

José Such, MD, PhD
Bruce A Runyon, MD
Section Editor
Keith D Lindor, MD
Deputy Editor
Anne C Travis, MD, MSc, FACG, AGAF


Ascites is defined as the pathologic accumulation of fluid in the peritoneal cavity [1]. It is the most common complication of cirrhosis, which is the most common cause of ascites in the United States, accounting for approximately 85 percent of cases [1]. Within 10 years after the diagnosis of compensated cirrhosis, about 50 percent of patients will have developed ascites [2].

The development of ascites is the final consequence of a series of anatomic, pathophysiologic, and biochemical abnormalities occurring in patients with cirrhosis. The two older theories of ascites formation, the underfill theory [3] and the overflow theory [4], appear to be relevant at different stages of the natural history of cirrhosis [5]. However, the most recent theory, the arterial vasodilation hypothesis, appears to match best with the actual hemodynamic data and has become the most widely accepted theory [6].

The formation of ascites is governed by the same principles as edema formation at other sites: net capillary permeability and the hydraulic and oncotic pressure gradients. (See "Pathophysiology and etiology of edema in adults".)


The development of portal hypertension (PHT) is the first step toward fluid retention in the setting of cirrhosis. Patients with cirrhosis but without PHT do not develop ascites or edema [7]. A portal pressure >12 mmHg appears to be required for fluid retention [7,8]; on the other hand, ascites will usually disappear if portal pressure is reduced below 12 mmHg, eg, after a surgical or radiologic portosystemic shunt [9]. Sinusoidal hypertension appears to be required for fluid retention to occur; presinusoidal portal hypertension, as in portal vein thrombosis, does not result in ascites formation in the absence of another predisposing factor.

PHT leads to profound changes in the splanchnic circulation. Although it was formerly thought that PHT was due solely to a mechanical obstruction to portal flow, data from animal models provide evidence for a component of increased portal venous inflow as a consequence of splanchnic arterial vasodilation [10,11].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Dec 16, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.
  2. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122.
  3. SHERLOCK S, SHALDON S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 1963; 4:95.
  4. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann NY Acad Sci 1970; 170:292.
  5. Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Treatment, Feldman, M, Friedman, LS, Brandt, LJ (Eds), WB Saunders, Philadelphia 2010. p.1517.
  6. Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53:1135.
  7. Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.
  8. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249.
  9. Reichle FA, Owen OE. Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts. Ann Surg 1979; 190:523.
  10. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120.
  11. Cardenas A, Gines P. Pathobiology, Evaluation, and Treatment. In: Portal Hypertension, Sanyal AJ, Shah VH (Eds), Humana Press, 2005. p.65.
  12. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20:1356.
  13. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.
  14. KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.
  15. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.
  16. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78:92.
  17. Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17:788.
  18. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287.
  19. Kravetz D, Arderiu M, Bosch J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987; 252:G257.
  20. Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986; 70:477.
  21. Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986; 90:687.
  22. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104:869.
  23. Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102:303.
  24. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776.
  25. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121.
  26. Ros J, Jiménez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21:554.
  27. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139.
  28. Clària J, Jiménez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15:343.
  29. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104:1750.
  30. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103:235.
  31. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223.
  32. Francés R, Muñoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53:860.
  33. Úbeda M, Muñoz L, Borrero MJ, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010; 52:2086.
  34. Battista S, Bar F, Mengozzi G, et al. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. J Hepatol 1995; Suppl 1:73 (A).
  35. Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47:978.
  36. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208.
  37. Angeli P, Brun P, Cesari M, et, al. Prevalence of bacteria DNA in patients with cirrhosis and refractory ascites and its role in the development of caridac and renal dysfunction. Hepatology 2010; 52:342A (abstract).
  38. Such J, Francés R, Muñoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36:135.
  39. Francés R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39:484.
  40. Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52:2044.
  41. Zapater P, Frances R, Gonzalez-Navajas JM, et, al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2010; 48:1924.
  42. Guarner C, González-Navajas JM, Sánchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44:633.
  43. Asbert M, Ginès A, Ginès P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.
  44. Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.
  45. Arroyo V, Bosch J, Gaya-Beltrán J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.
  46. Wong F, Massie D, Hsu P, Dudley F. Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 1994; 20:873.
  47. Wong F, Liu P, Tobe S, et al. Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology 1994; 19:312.
  48. Wensing G, Lotterer E, Link I, et al. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26:1149.
  49. Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012; 55:1019.
  50. Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237.
  51. Arroyo V, Clària J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:44.
  52. Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.
  53. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.
  54. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32.
  55. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.
  56. Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17:219.
  58. Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35.
  59. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25:880.
  60. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.
  61. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.